Update on Phase 3 GY004 for Cediranib and LYNPARZA® (olaparib) in Platinum-Sensitive Relapsed Ovarian Cancer
Go back to Update on Phase 3 GY004 for Cediranib and LYNPARZA® (olaparib) in Platinum-Sensitive Relapsed Ovarian Cancer| Merck & Co. (NYSE: MRK) | Delayed: 128.50 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $128.50 | 52 Week High | $65.46 | |||
| Open | $128.50 | 52 Week Low | $47.97 | |||
| Day High | $128.50 | P/E | 87.41 | |||
| Day Low | $128.50 | EPS | $1.47 | |||
| Volume | 4,870 | |||||
